Bicatero 50mg Tablet

Most side effects caused by the Bicatero 50mg tablet don't require medical attention and may vanish upon your adjustment to the medicine. Consult your doctor immediately if you're unable to deal with these symptoms or if they persist.

• Decreased appetite
  
• Dizziness Nocturia (increased urge to urinate during the night)
  
• Edema (swelling)
  
• Anemia (low number of red blood cells)
  
• Rash
  
• Hot flashes
  
• Nausea
  
• Weaknes Abdominal pain
  
• Constipation

​Take the Bicatero 50mg tablet as prescribed by your health professional. Ensure you take this cancer-fighting formulation in the same amount as directed by your physician. In case of an overdose, the patient is advised to consult a general practitioner as soon as possible if any unusual symptoms occur.

Bicatero 50mg tablet should be swallowed as a whole. Let your doctor know if you have liver, thyroid, kidney disease, etc, or are on some other medications. Bicatero 50mg tablet is not recommended for pregnant and breastfeeding women.

Bicatero 50mg tablet functions by decreasing the effect of testosterone (male hormone) in the body. It does this by blocking the action of testosterone at specific sites, which slows down or prevents hormone-related changes in the human body. As a result, certain cells or tissues may be affected.

It is advisable to avoid missing any dose of Bicalutamide 50mg however in case you missed a dose consult your doctor immediately.

1. Bilusic M, Toney NJ, Donahue RN, Wroblewski S, Zibelman M, Ghatalia P, Ross EA, Karzai F, Madan RA, Dahut WL, Gulley JL, Schlom J, Plimack ER, Geynisman DM. (2023). A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1). Prostate Cancer Prostatic Dis. 25(4):735-740. Epub.
   
2. Furr BJ, Tucker H. (2022). The preclinical development of bicalutamide: pharmacodynamics and mechanism of action. Urology. 1996 Jan;47(1A Suppl):13-25; discussion 29-32 - https://pubmed.ncbi.nlm.nih.gov/8560673/
   
3. Furr BJ. (2025). The development of Casodex (bicalutamide): preclinical studies. Eur Urol. 1996;29 Suppl 2:83-95 - https://pubmed.ncbi.nlm.nih.gov/8717469/
   
4. Kotake T, Usami M, Isaka S, Shimazaki J, Nakano E, Okuyama A, Okajima E, Kanetake H, Saitoh Y, Kumamoto Y, Orikasa S, Sakata Y, Hosaka M, Akaza H, Koiso K, Honma Y, Aso Y, Oishi K, Yoshida O, Naitoh S, Kumazawa J, Koyanagi T, Yachiku S, Shiraiwa Y, Tsukagoshi S. (2025). [Clinical early phase II study of bicalutamide (Casodex) in patients with prostatic cancer]. Hinyokika Kiyo.42(2):157-68. Japanese - https://pubmed.ncbi.nlm.nih.gov/8712092/
   
5. Lee S, Yoon SH, Cho JY, Shin SG, Jang IJ, Yu KS. (2024). Relative bioavailability and tolerability of two formulations of bicalutamide 50-mg tablets: a randomized-sequence, open-label, two-period crossover study in healthy Korean male subjects. Clin Ther. 32(14):2496-501 - https://pubmed.ncbi.nlm.nih.gov/21353117/
   
6. Marijo Bilusic et al. (2023). Bicalutamide with or without metformin for biochemical recurrence in prostate cancer patients (BIMET-1). JCO 38, 85-85(2020) - https://ascopubs.org/doi/10.1200/JCO.2020.38.6_suppl.85
   
7. Qian SB, Shen HB, Cao QF, Zhang L, Chen YF, Qi J. (2025). Bicalutamide 150 mg as secondary hormonal therapy for castration-resistant prostate cancer. Int Urol Nephrol. 47(3):479-84.
   
8. Soloway MS, Schellhammer PF, Smith JA Jr, Chodak GW, Vogelzang NJ, Kennealey GT. (2024). Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II noncomparative multicenter trial evaluating safety, efficacy, and long-term endocrine effects of monotherapy. J Urol. 154(6):2110-4.
   
9. Soloway MS, Schellhammer PF, Smith JA, Chodak GW, Kennealey GT. (2024). Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II multicenter trial. Urology. (1A Suppl):33-7; discussion 48-53.